Literature DB >> 16804071

Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian-Caucasian nondiabetic subjects.

Francesco Andreozzi1, Emanuela Laratta, Marina Cardellini, Maria A Marini, Renato Lauro, Marta L Hribal, Francesco Perticone, Giorgio Sesti.   

Abstract

We have investigated the relationships between plasma interleukin-6 (IL-6) levels and insulin sensitivity and insulin secretion in a cohort of Italian-Caucasian glucose-tolerant subjects. Insulin sensitivity was assessed by euglycemic-hyperinsulinemic clamp, and first-phase insulin secretion was measured by intravenous glucose tolerance test. Fasting plasma IL-6 concentration was negatively correlated with the rate of insulin-stimulated glucose disposal (M) (P = 0.001). The correlation remained statistically significant, while attenuated, after adjusting for sex, age, and BMI (P < 0.03); after an additional adjustment for free fatty acids (FFAs), a further attenuation was observed, but statistical significance was maintained (P < 0.044). Fasting plasma IL-6 concentration was positively correlated with first-phase insulin secretion assessed as acute insulin response (AIR) (P = 0.001). The correlation remained significant after adjusting for sex, age, and BMI (P = 0.003). To estimate the independent contribution of plasma IL-6 levels to AIR, we carried out forward stepwise linear regression analysis in a model that included sex, age, BMI, waist-to-hip ratio, FFAs, and insulin-stimulated glucose disposal. Only insulin sensitivity and plasma IL-6 concentration were independently associated with AIR, accounting, respectively, for 19.0 and 5.2% of its variation. These data indicate that IL-6 is associated in a reciprocal manner with the two pathophysiological components of type 2 diabetes, i.e., insulin resistance and insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804071     DOI: 10.2337/db06-0063

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  12 in total

1.  Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype.

Authors:  M E Street; C Spaggiari; M A Ziveri; M Rossi; C Volta; I Viani; G L Grzincich; C Sartori; M Zanzucchi; V Raia; C Terzi; G Pisi; E Zanetti; M C S Boguszewski; T O Kamoi; S Bernasconi
Journal:  J Endocrinol Invest       Date:  2011-04-06       Impact factor: 4.256

2.  Effect of iridoid glucoside on plasma lipid profile, tissue fatty acid changes, inflammatory cytokines, and GLUT4 expression in skeletal muscle of streptozotocin-induced diabetic rats.

Authors:  Ramalingam Sundaram; Palanivelu Shanthi; Panchanatham Sachdanandam
Journal:  Mol Cell Biochem       Date:  2013-04-27       Impact factor: 3.396

3.  The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes.

Authors:  Yen-Lin Chen; Jiunn-Diann Lin; Te-Lin Hsia; Frank Chiahung Mao; Chun-Hsien Hsu; Dee Pei
Journal:  Eur J Nutr       Date:  2013-03-14       Impact factor: 5.614

4.  Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats.

Authors:  Sushil K Jain; Justin L Rains; Jennifer L Croad
Journal:  Free Radic Biol Med       Date:  2007-05-18       Impact factor: 7.376

5.  Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice.

Authors:  S Franckhauser; I Elias; V Rotter Sopasakis; T Ferré; I Nagaev; C X Andersson; J Agudo; J Ruberte; F Bosch; U Smith
Journal:  Diabetologia       Date:  2008-04-24       Impact factor: 10.122

6.  Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant -174G>C with circulating glucose levels, interleukin-6 levels, and body mass index.

Authors:  Cornelia Huth; Thomas Illig; Christian Herder; Christian Gieger; Harald Grallert; Caren Vollmert; Wolfgang Rathmann; Yasmin H Hamid; Oluf Pedersen; Torben Hansen; Barbara Thorand; Christa Meisinger; Angela Doring; Norman Klopp; Henning Gohlke; Wolfgang Lieb; Christian Hengstenberg; Valeriya Lyssenko; Leif Groop; Helen Ireland; Jeffrey W Stephens; Ingrid Wernstedt Asterholm; John-Olov Jansson; Heiner Boeing; Matthias Mohlig; Heather M Stringham; Michael Boehnke; Jaakko Tuomilehto; Jose-Manuel Fernandez-Real; Abel Lopez-Bermejo; Luis Gallart; Joan Vendrell; Steve E Humphries; Florian Kronenberg; H-Erich Wichmann; Iris M Heid
Journal:  Ann Med       Date:  2009       Impact factor: 4.709

7.  Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway.

Authors:  Toshinobu Suzuki; Junta Imai; Tetsuya Yamada; Yasushi Ishigaki; Keizo Kaneko; Kenji Uno; Yutaka Hasegawa; Hisamitsu Ishihara; Yoshitomo Oka; Hideki Katagiri
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

8.  Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials.

Authors:  Rui Chen; Jinchuan Yan; Peijing Liu; Zhongqun Wang
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

9.  Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects.

Authors:  Elena Succurro; Francesco Andreozzi; Angela Sciacqua; Angela Sciaqua; Marta Letizia Hribal; Francesco Perticone; Giorgio Sesti
Journal:  Diabetes Care       Date:  2008-06-05       Impact factor: 19.112

10.  Relationship between grip strength and newly diagnosed nonalcoholic fatty liver disease in a large-scale adult population.

Authors:  Ge Meng; Hongmei Wu; Liyun Fang; Chunlei Li; Fei Yu; Qing Zhang; Li Liu; Huanmin Du; Hongbin Shi; Yang Xia; Xiaoyan Guo; Xing Liu; Xue Bao; Qian Su; Yeqing Gu; Huijun Yang; Yuntang Wu; Zhong Sun; Kaijun Niu
Journal:  Sci Rep       Date:  2016-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.